Merck pharmaceutical company: COVID-19 drug less effective than previously thought

It found that, after examining more than 1,400 adults, molnupiravir reduced the risk of hospitalization or death in patients with mild to moderate COVID-19 by 30 percent. Last month, Merck reported that, based on data from 775 patients, the study was found to be around 50 percent effective.

In a statement Friday, the pharmaceutical company said the interim analysis and additional studies continue to “maintain the efficacy and overall benefit-risk assessment of molnupiravir in treating mild to moderate COVID-19 in adults at high risk of disease progression.” It has been added that updated data on the efficacy of molnupiravir were made available to the Food and Drug Administration (FDA).

Merck & Co. and a partner of Ridgeback Biotherapeutics LP applied on October 11 to the FDA for approval of molnupiravir in the treatment of mild to moderate COVID-19 disease in adults who are at risk of developing the disease that may result in hospitalization.

The FDA’s advisory committee is expected to discuss the effectiveness of the COVID-19 pill next week.

Molnupiravir can be administered to patients at home, as opposed to Gilead Sciences Inc.’s remdesivir and monoclonal antibody therapies, which are administered by intravenous infusion, usually in a hospital or clinic. Treating patients at home avoids the risk of transmission of the virus to healthcare professionals and other patients.


About Banner Leon

Videogames entered his life in the late '80s, at the time of the first meeting with Super Mario Bros, and even today they make it a permanent part, after almost 30 years. Pros and defects: he manages to finish Super Mario Bros in less than 5 minutes but he has never finished Final Fight with a credit ... he's still trying.

Check Also

Ukraine. Russia. Marcin Przydacz: The risk of escalation is very high

Jakub Oworuszko, Interia: Will Russia attack Ukraine? Marcin Przydacz, deputy head of the Ministry of …

Leave a Reply

Your email address will not be published.